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Respiratory viral infection is a major cause of asthma exacerbations in both children and
adults. Among the respiratory viruses, inﬂuenza virus is a particularly important pathogen
due to its enormousmorbidity andmortality in annual epidemics.The swine-origin inﬂuenza
A virus, designated as A(H1N1)pdm09, emerged in the spring of 2009 and caused the ﬁrst
inﬂuenza pandemic in the 21st century. With the emergence of the novel A(H1N1)pdm09
virus, numerous epidemiologic studies detected asthma as a frequent comorbid condition
in patients infected with this virus. Here we review recent reports regarding asthma in
patients infectedwith inﬂuenzaA(H1N1)pdm09 virus, andwe discuss the utility of inﬂuenza
vaccines and antivirals.
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INTRODUCTION
Asthma is a chronic airway disease with the symptoms of repetitive
cough, wheezing and dyspnea, with reversible airway narrowing
accompanied by airway hyper-responsiveness (Ohta et al., 2011).
It is estimated that worldwide, approximately 300 million peo-
ple including both children and adults have asthma (Masoli et al.,
2004). Inhaled irritants, inhaled allergens, and microorganism
infections of the respiratory tract are common causes of asthma
exacerbations. Respiratory viral infection is closely associated
with asthma (Jacoby, 2002; Papadopoulos et al., 2011). Human
rhinovirus (HRV) is the most common virus in asthmatics of
all ages (Papadopoulos et al., 2011). Respiratory syncytial virus
and enterovirus are also frequently detected in infants, whereas
inﬂuenza virus seems to induce severe exacerbations, mostly in
adults (Papadopoulos et al., 2011).
Inﬂuenza virus causes inﬂuenza characterized by a sudden
onset of high fever and respiratory symptoms such as cough, sore
throat and coryza, as well as systemic symptoms such as headache,
muscle ache and fatigue. Inﬂuenza epidemics occur yearly dur-
ing the autumn and winter in temperate regions, whereas the
disease patterns in tropical and subtropical regions are less well
established (World Health Organization, 2009). Annual epidemics
result in approximately three to ﬁve million cases of severe ill-
ness and approximately 250,000 to 500,000 deaths, which occur
mostly among people age 65 or older (World Health Organization,
2009).
INFLUENZA A(H1N1)pdm09 VIRUS
Inﬂuenza A viruses can be subtyped according to their two major
surface glycoproteins, hemagglutinin (HA) and neuraminidase
(NA). Currently, there are 16 subtypes of HA (H1–H16) and nine
subtypes of NA (N1–N9), and all have been found in wild aquatic
birds, which are the natural reservoir of inﬂuenza A viruses. Only
two subtypes of these viruses (H1N1 and H3N2) are currently
circulating in humans, as seasonal inﬂuenza. Inﬂuenza A viruses
have negative-sense, single-stranded, and eight-segmented RNAs
as the genome (Lamb and Choppin, 1983). It is known that simul-
taneous infection of a single cell by two distinct inﬂuenzaA viruses
can lead to gene reassortment (Hause et al., 2012), which results
in the generation of a novel inﬂuenza virus strain. It is believed
that most human pandemic inﬂuenza A viruses arose in this
manner.
In March and early April 2009, a novel swine-origin inﬂuenza
A(H1N1) virus, designated as A(H1N1)pdm09, emerged in Mex-
ico and the United States (Centers for Disease Control and
Prevention, 2009) and rapidly spread worldwide. Genetic and evo-
lutionary analyses revealed that this pandemic virus contains a
combination of gene segments which had not been reported pre-
viously in swine or human inﬂuenza viruses in any part of the
world. In the late 1990s, reassortment among North American
avian (unknown subtype), human A(H3N2), and classical swine
A(H1N1) viruses resulted in triple reassortant swineA(H3N2) and
A(H1N2) viruses.
A triple reassortant swine A(H1N2) virus then reassorted
with a Eurasian avian-like swine A(H1N1) virus, resulting in
A(H1N1)pdm09 virus (Garten et al., 2009; Smith et al., 2009;
Figure 1). The polymerase basic 2 (PB2) and polymerase acidic
(PA) gene segments were derived from the avian virus lineage,
whereas the polymerase basic 1 (PB1) gene segment was from
human A(H3N2) virus. The HA, nucleoprotein (NP), and non-
structural protein (NS) gene segments were from classical swine
A(H1N1) virus. The NA and matrix (M) gene segments were from
the Eurasian avian-like swine A(H1N1) virus.
A(H1N1)pdm09 virus has none of the known hallmarks of vir-
ulent inﬂuenza viruses such as highly pathogenic avian A(H5) and
A(H7) viruses, except for an amino acid substitution of aspar-
tic acid by glycine at position 222 (D222G) in the HA, which
was observed in severe and fatal cases with high frequency. The
D222G substitution changes the receptor binding speciﬁcity of the
virus from α2–6 (mammalian type) to α2–3 (avian type) sialylated
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FIGURE 1 | A(H1N1)pdm09 virus and asthma.The reassortment of a triple
reassortant swine A(H1N2) virus with a Eurasian avian-like swine A(H1N1)
virus resulted in the pandemic A(H1N1) 2009 virus. The colored solid rods
represent the gene segments as follows. Classical swine A(H1N1) virus: red.
North American avian virus: yellow. Human A(H3N2) virus: green. Eurasian
avian-like swine A(H1N1) virus: purple. Airway inﬂammation induced by the
viral infection causes an exacerbation of asthma. Early treatment with antiviral
drugs and vaccination represents the mainstay of management.
glycans (Puzelli et al., 2010; World Health Organization, 2010;
Belser et al., 2011). This amino acid substitution may result in
a more efﬁcient infection of human alveolar type II pneumocytes,
which express avian type receptors, reducing the availability of
progenitor cells for essential lung functions and thus leading to
severe pulmonary impairment.
We recently reported thatA(H1N1)pdm09 viral isolates derived
from fatal casesmanifested sporadic amino acid changes in thePB2
and PA proteins (which are subunits of viral RNA polymerase)
more frequently than those derived from mild cases (Obuchi et al.,
2012). More recently, reassortant viruses generated by reverse
genetics have shown that lysine or isoleucine at position 340 or
649 of the PB2, respectively, and threonine at position 667 of
the PB2 also contribute to virulence in a mouse model (Uraki
et al., 2013). Further studies are needed to elucidate the role of
the viral RNA polymerase of A(H1N1)pdm09 virus as a virulence
factor.
A(H1N1)pdm09 VIRAL INFECTION AND ASTHMA
Widespread activity of pandemic A(H1N1) 2009 occurred and
reached its peak a couple of months earlier than the usual sea-
sonal inﬂuenza in the northern hemisphere, from April 2009 to
January 2010 (Amato-Gauci et al., 2011; Jhung et al., 2011). The
A(H1N1)pdm09 viral infection was considered a mild disease,
similar to seasonal inﬂuenza. However,many severe and fatal cases
were observed not only in the high-risk groups, but also among
healthy children and young adults during the pandemic waves
(Athanasiou et al., 2010; Reichert et al., 2010).
Asthma was one of the most common underlying medical con-
ditions among patients hospitalized with A(H1N1)pdm09 viral
infection in 2009 worldwide (Jain et al., 2009; Van Kerkhove et al.,
2011). Kloepfer et al. (2012) reported that children with asthma
had increased susceptibility to A(H1N1)pdm09 viral infection.
They collected weekly nasal samples from 161 children (95 with
asthma and 66 without asthma) between September 5 and Octo-
ber 24, 2009, and a total of 346 viral infections were detected.
The majority were HRV (62%), followed by enterovirus (12%),
A(H1N1)pdm09 virus (10%), adenovirus (2%), and others. Over-
all, 34% of the children were infected with A(H1N1)pdm09 virus
during the study period. The incidence of A(H1N1)pdm09 viral
infection was signiﬁcantly higher in the children with asthma
(41%) than in the children without asthma (24%), whereas the
incidences of HRV (95% each) and the other viral infections (47%
vs. 41%) were similar.
A Canadian group reported that children admitted to a hospital
with A(H1N1)pdm09 viral infection tended to have pre-existing
asthma to a greater extent compared to the children with sea-
sonal inﬂuenza A viral infection (15% vs. 5%), although there
was no signiﬁcant difference in the severity of pre-existing asthma
between the groups of children with these infections (Morris et al.,
2012). An age-matched control study in Hong Kong demonstrated
that hospitalized children with A(H1N1)pdm09 viral infection
were more susceptible to asthma exacerbations compared to
seasonal A(H1N1) (8.1 vs. 1.0%) or A(H3N2) (8.1 vs. 1.0%)
viral infection (Chiu et al., 2011). A Japanese group reported
similar ﬁndings (Hasegawa et al., 2011). It seems likely that
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A(H1N1)pdm09 viral infection rather thanA(H1N1) orA(H3N2)
viral infection may enhance the already elevated inﬂammatory
response and worsen the symptoms in asthma. The underly-
ing mechanisms of increased susceptibility to A(H1N1)pdm09
viral infection and the asthma exacerbation remain to be
explored.
In contrast, it is not clear whether A(H1N1)pdm09 viral infec-
tion can frequently cause the development of asthma compared
to seasonal A(H1N1) or A(H3N3) viral infection. The study by
Hasegawa et al. (2011) mentioned above showed that 7 (31.8%)
of 22 asthmatic children with A(H1N1)pdm09 viral infection
admitted to a hospital between October and December 2009 were
not previously diagnosed with asthma. The sample size of that
study is small, and thus a larger patient population must be
studied.
Inﬂuenza A viral infection induces the production of inter-
leukin 1 beta (IL-1β), IL-6, IL-8, tumor necrosis factor-alpha
(TNF)-α, histamine, protease, interferon (IFN)-α, and IFN-
gamma (IFN-γ) from airway epithelial cells and other cells
includingperipheral bloodbasophils (Yamaya,2012). These proin-
ﬂammatory cytokines, monokines, and inﬂammatory substances
may contribute to the development of airway inﬂammation, dam-
aging the barrier function and leading to a subsequent asthma
attack (Figure 1).
Camp et al. (2013) examined the phenotypic differences in vir-
ulence and immune response in A(H1N1)pdm09 virus isolates
obtained from hospitalized patients with severe pneumonia. In
that study, all viral isolates showed high similarity in nucleic acid
sequences in viral gene and replication levels in nasal turbinates
and lung, but the isolates’ virulence and host responses in mice
varied. Proinﬂammatory cytokines such as IL-1β, TNF-α and
a keratinocyte-derived chemokine (KC) were expressed early in
mice infected with virulent isolates compared to avirulent isolates,
including a vaccine strain of A(H1N1) virus in the 2008–2009
season, A/Brisbane/59/2007. In vitro experiments demonstrated
that a virulent isolate – but not an avirulent isolate – was able to
replicate productively in macrophages, suggesting that viral sus-
ceptibility to macrophages may be one of the key determinants of
their pathogenicity (Camp et al., 2013).
UTILITY OF INFLUENZA VACCINES AND ANTIVIRAL DRUGS
IN PATIENTS WITH ASTHMA
Many respiratory viruses are associatedwith asthmaexacerbations,
among which the inﬂuenza virus is the only virus for which both
vaccines and antiviral drugs are available (Figure 1). Two types of
inﬂuenza vaccines are currently available; inactivated vaccine and
live, attenuated vaccine. The live, attenuated nasal-spray inﬂuenza
vaccine has been approved for use in the United States since
2003. However, it has not been recommended in high-risk groups
including asthmatics because its safety is not fully demonstrated.
The widespread use of inactivated inﬂuenza vaccines contain
a trivalent mixture of strains of A(H1N1)pdm09, A(H3N2),
and type B viruses likely to circulate during the next inﬂuenza
season. Many studies indicated that no increase in asthma exac-
erbations was reported for both vaccinated children and adults
(American Lung Association Asthma Clinical Research Centers,
2001; Kramarz et al., 2001; Hak et al., 2005).
A randomized, open-label study to investigate the safety and
immunogenicity of two administrations of an unadjuvanted, inac-
tivatedA(H1N1)pdm09 virus vaccinewas conducted in theUnited
States (Busse et al., 2011). The results indicated that both the 15-
μg (standard dose) and 30-μg vaccine doses generally provided
excellent seroprotection against viral antigen 21 days after a single
immunization in patients (12 to 79 years of age) with mild-to-
moderate asthma. In patients with severe asthma, the response
to the 15-μg dose was lower than that to the 30-μg dose. The
authors of that study did not identify any safety concerns with
the A(H1N1)pdm09 vaccine. Collectively, the ﬁndings described
above indicate that inactivated inﬂuenza vaccines arewell tolerated
in patients with asthma.
Speciﬁc antiviral drugs against inﬂuenza viruses could be
used for the treatment and prophylaxis for inﬂuenza. Based on
their chemical properties and spectra of activity against inﬂuenza
viruses, the drugs can be classiﬁed into two categories: the M2 ion
channel inhibitors, i.e., adamantanes (amantadine and rimanta-
dine) and theNA inhibitors, i.e., zanamivir, oseltamivir, peramivir,
and laninamivir. Currently, the NA inhibitors are exclusively used
for the treatment and prophylaxis of inﬂuenza because the cir-
culating strains of A(H1N1)pdm09 and A(H3N2) viruses have a
known amino acid substitution of serine by asparagines at position
31 in the M2 protein, which confers resistance to the adamantanes.
Few studies have examined the safety of NA inhibitors
in patients with asthma. A double-blind, placebo-controlled
crossover study indicated that zanamivir inhaled as a dry pow-
der did not signiﬁcantly affect the pulmonary function and airway
responsiveness of subjects (19 to 49 years of age) with mild or
moderate asthma (Cass et al., 2000). However, a number of stud-
ies suggested that the use of NA inhibitors was beneﬁcial in
hospitalized patients with A(H1N1)pdm09 viral infection, par-
ticularly when they are started within 48 h after the onset of
illness (Domínguez-Cherit et al., 2009; Jain et al., 2009; Louie
et al., 2010). Accordingly, WHO recommended that for patients
at increased risk for severe or complicated illness, treatment with
oseltamivir or zanamivir should be started as soon as possible
after the onset of illness (Writing Committee of the WHO Con-
sultation on Clinical Aspects of Pandemic (H1N1) 2009 inﬂuenza,
2010). AlthoughA(H1N1)pdm09 virus resistance toNA inhibitors
has been detected at very low frequency among circulating viral
strains (World Health Organization, 2013b), there is concern
about the recent report that oseltamivir-resistant A(H1N1)pdm09
viral mutants were detected in untreated patients and from a few
clusters in some countries (Samson et al., 2013).
CLOSING REMARKS
Epidemiological studies as described above demonstrated that
A(H1N1)pdm09 viral infection is closely associated with asthma
in both children and adults. Although A(H1N1)pdm09 virus has
not shown a high mortality rate similar to that of the highly
pathogenic avian inﬂuenza virus of the H5N1 subtype, patients
with A(H1N1)pdm09 viral infection were more susceptible to
asthma exacerbation compared to A(H1N1) or A(H3N2) viral
infection. Detailed analyses of virus-host interactions are needed
to elucidate the mechanism underlying A(H1N1)pdm09 viral
infection-induced asthma.
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Since March 31, 2013 when the public health authorities of
China reported three cases of human infection with an avian
inﬂuenza A(H7N9) virus, a total of 135 human cases includ-
ing 44 fatal cases have been reported in China and Taiwan as of
August 12, 2013 (World Health Organization, 2013a). The current
avian inﬂuenza viral infections in humans present considerable
pathogenic potential with high mortality rates, suggesting that the
pandemic viruses, if they emerge in human beings, could also
present high pathogenicity and result in an excessive number of
deaths in high-risk groups, including asthmatics. It will therefore
be important to make preparations for drugs and vaccines for
anti-inﬂuenza treatments and the prophylaxis of inﬂuenza.
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